BACKGROUND: Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5-fluorouracil or alone in patients previously treated with afluoropyrimidine. We compared toxicity (particularly diarrhoea), quality of life, and efficacy of combination chemotherapy and irinotecan in these patients. METHODS: In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly. Toxicity was evaluated every treatment cycle; QOL and response 6-weekly. Analysis was by intention to treat. The trial, amended from a larger factorial design, was terminated early due to slow recruitment. Results were also combined with other second-line irinotecan trials. FINDINGS: We randomised 44 patients to combination and 45 to single agent. Eight patients in the irinotecan arm and 4 in the combination arm had grade 3/4 diarrhoea (P=0.24). Treatment groups did not differ significantly in overall QOL changes, response rate or progression free or overall-survival. In a systematic review of 29 trials of second-line irinotecan-based treatment, single-agent irinotecan was associated with more diarrhoea and alopecia than the combination but efficacy was similar. INTERPRETATION: Combination treatment compared with single-agent irinotecan reduces alopecia and diarrhoea without compromising efficacy on clinical outcomes. Both regimens remain as reasonable treatment options. FUNDING: Research grant (Pfizer).
RCT Entities:
BACKGROUND: Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5-fluorouracil or alone in patients previously treated with a fluoropyrimidine. We compared toxicity (particularly diarrhoea), quality of life, and efficacy of combination chemotherapy and irinotecan in these patients. METHODS: In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly. Toxicity was evaluated every treatment cycle; QOL and response 6-weekly. Analysis was by intention to treat. The trial, amended from a larger factorial design, was terminated early due to slow recruitment. Results were also combined with other second-line irinotecan trials. FINDINGS: We randomised 44 patients to combination and 45 to single agent. Eight patients in the irinotecan arm and 4 in the combination arm had grade 3/4 diarrhoea (P=0.24). Treatment groups did not differ significantly in overall QOL changes, response rate or progression free or overall-survival. In a systematic review of 29 trials of second-line irinotecan-based treatment, single-agent irinotecan was associated with more diarrhoea and alopecia than the combination but efficacy was similar. INTERPRETATION: Combination treatment compared with single-agent irinotecan reduces alopecia and diarrhoea without compromising efficacy on clinical outcomes. Both regimens remain as reasonable treatment options. FUNDING: Research grant (Pfizer).
Authors: Simone Mocellin; Zora Baretta; Marta Roqué I Figuls; Ivan Solà; Marta Martin-Richard; Sara Hallum; Xavier Bonfill Cosp Journal: Cochrane Database Syst Rev Date: 2017-01-27
Authors: M T King; D S J Costa; N K Aaronson; J E Brazier; D F Cella; P M Fayers; P Grimison; M Janda; G Kemmler; R Norman; A S Pickard; D Rowen; G Velikova; T A Young; R Viney Journal: Qual Life Res Date: 2016-01-20 Impact factor: 4.147
Authors: Noha Rashad; Mohamed Abdulla; Mohamed Farouk; Yasser Elkerm; Salem Eid Salem; Maha Yahia; Amr S Saad; Ahmed Hassan Abdel Aziz; Ghada Refaat; Ibrahim Awad; Maha ElNaggar; Khaled Kamal; Basel Refky; Mohamed Abdelkhalek; Ahmed Touny; Loay Kassem; Emad Shash; Abdelhay A Abdelhay; Bahaa Eldin Mahmoud; Karima Oualla; Nesrine Chraiet; Hussein AwadElkarim H Maki; Yasser Abdel Kader Journal: Cancer Manag Res Date: 2022-02-28 Impact factor: 3.989
Authors: Shouki N Bazarbashi; Ali M Alzahrani; Mohammed M Rahal; Ahmed S Al-Shehri; Ali H Aljubran; Nasser A Alsanea; Omar A Al-Obeed; Magdy S Kandil; Jamal E Zekri; Ashwaq A Al Olayan; Abdullah A Alsharm; Khaled S Balaraj; Mosa A Fagih Journal: Saudi Med J Date: 2014-12 Impact factor: 1.484